Biodesix will present lung cancer diagnostics and breast cancer assay development data at upcoming scientific conferences.
Quiver AI Summary
Biodesix, Inc. has announced upcoming presentations at two major medical conferences focusing on advancements in lung and breast cancer diagnostics. At the North American Conference on Lung Cancer (NACLC) from December 5-7, the company will showcase clinical utility data for its Nodify Lung® tests, emphasizing improved risk classification for lung nodules to enable earlier lung cancer detection. Additionally, at the San Antonio Breast Cancer Symposium (SABCS) from December 9-12, Biodesix will introduce a new ultra-sensitive ESR1 assay designed for monitoring treatment resistance in advanced breast cancer. The company's ongoing research efforts recently earned recognition at the ISPOR Europe 2025 Meeting, highlighting healthcare challenges related to pulmonary nodules. Biodesix aims to enhance clinical care and outcomes through its diagnostic solutions, including Nodify Lung® and other development services for biopharmaceutical partners.
Potential Positives
- Presentation of clinical utility data for Nodify Lung® tests at a major conference may enhance the company's credibility and visibility in the lung cancer diagnostic market.
- Introduction of a new ultra-sensitive ESR1 assay for breast cancer treatment resistance monitoring showcases Biodesix's commitment to innovation and addressing critical healthcare needs.
- Recognition for research excellence at the ISPOR Europe 2025 Meeting underscores the quality and impact of Biodesix's work in the diagnostic field, potentially attracting more partnerships and customers.
Potential Negatives
- Presentation of clinical utility data implies a need for further validation of Nodify Lung® tests, which could raise concerns about their current efficacy and market readiness.
- Highlighting significant healthcare costs and gaps in pulmonary nodule surveillance may reflect poorly on existing diagnostic practices, potentially undermining confidence in current offerings.
- The focus on developing new tests signals the possibility of limitations in existing products, suggesting ongoing drawbacks in Biodesix's current diagnostic capabilities.
FAQ
What is Nodify Lung® and its significance?
Nodify Lung® is a test for lung nodule risk assessment that aids in the early detection of lung cancer.
When and where will Biodesix present its research?
Biodesix will present at the North American Conference on Lung Cancer from December 5 - 7, 2025, in Chicago, IL.
What new developments in breast cancer diagnostics will be showcased?
The company will present a new ultra-sensitive ESR1 assay for monitoring breast cancer treatment resistance at SABCS.
What awards did Biodesix recently receive?
Biodesix received a Best General Poster Research Presentation and a Top 5% Research Certificate at ISPOR Europe 2025.
How does Biodesix support personalized care for patients?
Biodesix offers diagnostic tests and development services that enhance clinical decision-making and improve patient outcomes in lung disease.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BDSX Insider Trading Activity
$BDSX insiders have traded $BDSX stock on the open market 14 times in the past 6 months. Of those trades, 4 have been purchases and 10 have been sales.
Here’s a breakdown of recent trading of $BDSX stock by insiders over the last 6 months:
- JACK W SCHULER has made 4 purchases buying 3,648,790 shares for an estimated $2,611,422 and 0 sales.
- SCOTT HUTTON (President & CEO) has made 0 purchases and 2 sales selling 3,961 shares for an estimated $3,010.
- ROBIN HARPER COWIE (CFO, Sec'y & Treasurer) has made 0 purchases and 2 sales selling 1,038 shares for an estimated $792.
- KIERAN O'KANE (Chief Commercial Officer) has made 0 purchases and 2 sales selling 501 shares for an estimated $388.
- GARY ANTHONY PESTANO (Chief Development Officer) has made 0 purchases and 2 sales selling 465 shares for an estimated $359.
- CHRIS VAZQUEZ (Chief Accounting Officer) has made 0 purchases and 2 sales selling 241 shares for an estimated $193.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$BDSX Revenue
$BDSX had revenues of $21.8M in Q3 2025. This is an increase of 19.93% from the same period in the prior year.
You can track BDSX financials on Quiver Quantitative's BDSX stock page.
$BDSX Hedge Fund Activity
We have seen 11 institutional investors add shares of $BDSX stock to their portfolio, and 43 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TELEMARK ASSET MANAGEMENT, LLC added 414,124 shares (+inf%) to their portfolio in Q3 2025, for an estimated $3,126,636
- VANGUARD GROUP INC added 181,904 shares (+inf%) to their portfolio in Q3 2025, for an estimated $1,373,375
- OPALEYE MANAGEMENT INC. removed 161,250 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $910,095
- MONASHEE INVESTMENT MANAGEMENT LLC removed 100,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $755,000
- SILVERARC CAPITAL MANAGEMENT, LLC removed 53,518 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $404,060
- PERKINS CAPITAL MANAGEMENT INC added 52,633 shares (+inf%) to their portfolio in Q3 2025, for an estimated $397,379
- GSA CAPITAL PARTNERS LLP added 48,342 shares (+inf%) to their portfolio in Q3 2025, for an estimated $364,982
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
Clinical utility data for Nodify Lung ® tests to be presented at North American Conference on Lung Cancer (NACLC) highlighting potential for earlier diagnosis of lung cancer
Development data for a new ultra-sensitive ESR1 assay for breast cancer treatment resistance monitoring to be presented at San Antonio Breast Cancer Symposium (SABCS)
LOUISVILLE, Ky., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announces several poster presentations on lung cancer diagnostics and new research on breast cancer diagnostics at upcoming scientific meetings.
At the 2025 North American Conference on Lung Cancer (NACLC), December 5 - 7, in Chicago, IL, Biodesix will present new findings on its on-market Nodify Lung ® tests, with data that spotlight the importance of timely, accurate lung nodule risk classification to support the early detection of lung cancer:
-
Refining Post-test Probability of Lung Cancer Using Post-Market Data from a Blood-based Biomarker Test in Pulmonary Nodule Patients.
Authors: Michael N. Kammer, PhD ( Biodesix Head of Radiomics and Presenter ); Trevor Pitcher, PhD; Gary Pestano, PhD; Laura Peek, PhD; James R. Jett, MD, MS, FCCP; Steven C. Springmeyer, MD, FCCP.
-
Modeling the Impact of an Autoantibody Blood Test for Lung Cancer on Time to Diagnosis in Pulmonary Nodule Assessment: A Multi-Cohort Analysis.
Authors: Kathryn Long, MD (Presenter); Gerard A. Silvestri, MD, MS, Master FCCP; Michael N. Kammer, PhD; Trevor Pitcher, PhD; James Jett, MD; Viswam S. Nair, MD.
The company will also present data on the development of a new ultra-sensitive ESR1 test for initial detection and monitoring of the mutations in HR+/HER2- advanced breast cancers at the San Antonio Breast Cancer Symposium , December 9 -12, San Antonio, TX. This innovative test is now available to biopharmaceutical customers as part of the company’s Development Services offering:
-
Poster Session 4, PS4-02-29:
Development of an ultra-sensitive droplet digital PCR test for monitoring ESR1 variants in liquid biopsies
.
Authors: Leisa Jackson ( Biodesix Staff Scientist and Presenter), Helen Halpin, and Gary Pestano, PhD.
In addition, at the recent International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2025 Meeting in November, Biodesix was awarded two distinguished recognitions: a Best General Poster Research Presentation and a Top 5% Research Certificate. The presented research highlighted the significant healthcare costs associated with pulmonary nodules and the widespread lack of appropriate follow-up. These gaps in nodule surveillance contribute to delayed diagnoses and increased downstream clinical and economic burden. ISPOR will publish all award-winning research in their December 2025 conference supplement issue of Value in Health .
-
PT5: Pulmonary Nodule (PN)-Related and Lung Cancer-Related Workup Costs Within the Two-Year Period After Diagnosis of a PN in the United States
Author: Kimberly Le, MBA, MS, PharmD ( Biodesix Director of HEOR and Presenter ).
About Biodesix:
Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests , marketed as Nodify Lung ® Nodule Risk Assessment and IQLung ® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit biodesix.com.
Biodesix Contacts:
Media:
Natalie St. Denis, Director Corporate Communications, Biodesix
[email protected]
(720) 925-9285
Investors:
Chris Brinzey, Partner, ICR
[email protected]
(339) 970-2843
